Targeting the TNF/IAP Pathway Synergizes with Anti-CD3 Immunotherapy in T Cell Acute Lymphoblastic Leukemia

To find out actionable targets able to re-enforce leukemic cells vulnerability to T-ALL with anti-CD3 mAbs, including the clinically relevant Teplizumab, researchers identified the molecular program induced by T-ALL with anti-CD3 mAbs in PDXs-derived from T-ALL cases.